Article

Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children

University of Colorado School of Medicine, Aurora, CO 80045-0508, United States.
Vaccine (Impact Factor: 3.49). 08/2008; 26(33):4210-7. DOI: 10.1016/j.vaccine.2008.05.054
Source: PubMed

ABSTRACT HIV-infected children (N=243), >or=5 to <18 years old, receiving stable antiretroviral therapy, were stratified by immunologic status and randomly assigned to receive intranasal live attenuated influenza vaccine (LAIV) or intramuscular trivalent inactivated influenza vaccine (TIV). The safety profile after LAIV or TIV closely resembled the previously reported tolerability to these vaccines in children without HIV infection. Post-vaccination hemagglutination inhibition (HAI) antibody responses and shedding of LAIV virus were also similar, regardless of immunological stratum, to antibody responses and shedding previously reported for children without HIV infection. LAIV should be further evaluated for a role in immunizing HIV-infected children.

0 Followers
 · 
73 Views

Full-text (2 Sources)

Download
36 Downloads
Available from
May 26, 2014